These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
704 related items for PubMed ID: 17394231
1. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P. Arthritis Rheum; 2007 Apr 15; 57(3):448-53. PubMed ID: 17394231 [Abstract] [Full Text] [Related]
2. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P. Arthritis Rheum; 2005 Jan 15; 52(1):42-8. PubMed ID: 15641046 [Abstract] [Full Text] [Related]
3. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register. Arthritis Rheum; 2006 Jun 15; 54(6):1786-94. PubMed ID: 16736520 [Abstract] [Full Text] [Related]
4. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T. Arthritis Rheum; 2007 Feb 15; 56(2):448-52. PubMed ID: 17265480 [Abstract] [Full Text] [Related]
5. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ. Arthritis Rheum; 2003 Jun 15; 48(6):1493-9. PubMed ID: 12794815 [Abstract] [Full Text] [Related]
6. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA. J Rheumatol; 2004 Dec 15; 31(12):2356-9. PubMed ID: 15570634 [Abstract] [Full Text] [Related]
7. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ. Arthritis Rheum; 2004 Feb 15; 50(2):353-63. PubMed ID: 14872476 [Abstract] [Full Text] [Related]
8. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark. Arthritis Rheum; 2010 Jan 15; 62(1):22-32. PubMed ID: 20039405 [Abstract] [Full Text] [Related]
9. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group. Arthritis Rheum; 2006 Sep 15; 54(9):2793-806. PubMed ID: 16947627 [Abstract] [Full Text] [Related]
10. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Harley CR, Frytak JR, Tandon N. Am J Manag Care; 2003 Oct 15; 9(6 Suppl):S136-43. PubMed ID: 14577718 [Abstract] [Full Text] [Related]
11. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Panminerva Med; 2006 Jun 15; 48(2):129-35. PubMed ID: 16953150 [Abstract] [Full Text] [Related]
12. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Arthritis Rheum; 2005 Apr 15; 52(4):1227-36. PubMed ID: 15818699 [Abstract] [Full Text] [Related]
13. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F. Ann Rheum Dis; 2009 Oct 15; 68(10):1547-52. PubMed ID: 18930989 [Abstract] [Full Text] [Related]
14. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK. Arthritis Rheum; 2005 Jan 15; 52(1):61-72. PubMed ID: 15641091 [Abstract] [Full Text] [Related]
15. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ, Etanercept Study 400 Investigators. Ann Rheum Dis; 2008 Feb 15; 67(2):182-8. PubMed ID: 17728331 [Abstract] [Full Text] [Related]
16. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Ann Rheum Dis; 2007 Feb 15; 66(2):249-52. PubMed ID: 16837489 [Abstract] [Full Text] [Related]
17. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Arthritis Rheum; 2004 Feb 15; 50(2):364-71. PubMed ID: 14872477 [Abstract] [Full Text] [Related]
18. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Rheumatology (Oxford); 2006 Dec 15; 45(12):1558-65. PubMed ID: 16705046 [Abstract] [Full Text] [Related]
19. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis]. Wallenius M, Rødevand E, Skomsvoll JF. Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836 [Abstract] [Full Text] [Related]
20. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Kristensen LE, Saxne T, Geborek P. Arthritis Rheum; 2006 Feb 16; 54(2):600-6. PubMed ID: 16447237 [Abstract] [Full Text] [Related] Page: [Next] [New Search]